Interestingly, we previously observed that high levels of the CysLT1 receptor are consistent with a poor prognosis, and in a xenograft model with colon cancer cells, CysLT1 receptor inhibition with the CysLT1 antagonist montelukast reduced the tumor burden in these mice, and treatment with montelukast resulted in reduced stemness in combination with reduced colony formation in colon cancer cells [10, 33–34]. This evidence concerns the gene CYSLTR1 and malignant colon neoplasm.